Xenetic Biosciences

113 articles about Xenetic Biosciences

• Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

  3/22/2024

  Xenetic Biosciences, Inc. today reported its financial results for the year ended December 31, 2023.

• Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

  1/17/2024

  Xenetic Biosciences, Inc. today announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of its systemic DNase program.

• Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

  11/10/2023

  Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter ended September 30, 2023.

• Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

  10/11/2023

  Xenetic Biosciences, Inc. today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences, will participate at the Virtual Investor Ask the CEO Conference on October 24, 2023 at 1:00 PM ET.

• Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Xenetic Biosciences, Inc. today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

• Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

  8/11/2023

  Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2023.

• Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

  7/5/2023

  Xenetic Biosciences, Inc. today announced that Jeffrey Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic Biosciences will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 10:00 AM ET.

• Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - May 12, 2023

  5/12/2023

  Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock.

• Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

  5/11/2023

  Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2023 and provided a business update.

• Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

  5/4/2023

  Xenetic Biosciences, Inc. announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform.

• Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

  5/3/2023

  Xenetic Biosciences, Inc. today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform.

• Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

  4/11/2023

  Xenetic Biosciences, Inc. today announced it has entered into a Research Funding and Option Agreement (the "Agreement") with The Scripps Research Institute ("TSRI") to advance the development of the Company's systemic DNase program as well as its DNase-armored CAR T program.

• Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

  3/23/2023

  Xenetic Biosciences, Inc. today reported its financial results for the full year 2022 and provided a business update.

• Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

  3/16/2023

  Xenetic Biosciences, Inc. today announced that it will participate in the Virtual Investor NETs in Cancer Spotlight Event on Wednesday, March 29, 2023 at 11:00 AM ET.

• Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

  1/17/2023

  Xenetic Biosciences, Inc. today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,001,543 titled, Method to Improve Safety and Efficacy of Anti-Cancer Therapy.

• Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

  1/5/2023

  Xenetic Biosciences, Inc. today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET.

• Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

  10/11/2022

  Xenetic Biosciences, Inc. today announced the signing of a patent assignment from CLS Therapeutics, Inc. ("CLS") to Xenetic related to Xenetic's previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets.

• Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

  10/4/2022

  Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.

• Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Xenetic Biosciences, Inc. announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

• Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/12/2022

  Xenetic Biosciences, Inc. today reported its financial results for the second quarter of 2022 and provided a business update.